Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 3, 2021

Novartis’ Kymriah trial shows response rates in follicular lymphoma

Kymriah is the first CAR-T to receive FDA approval for r/r acute lymphoblastic leukaemia and r/r diffuse large B-cell lymphoma. 

Novartis has reported that the primary analysis of the Phase II ELARA trial of Kymriah (tisagenlecleucel) showed a complete response rate (CRR) of 66% in relapsed or refractory (r/r) follicular lymphoma (FL) patients.

A US Food and Drug Administration-approved therapy, Kymriah is the first CAR-T to receive approval in two separate indications, r/r acute lymphoblastic leukaemia and r/r diffuse large B-cell lymphoma.

This one-time therapy is developed to boost the immune system of the patients to fight cancer.

The single-arm, multi-centre, open-label Phase II ELARA trial assessed the efficacy and safety of Kymriah in adults with r/r FL. This global trial enrolled subjects from more than 30 centres in 12 countries globally.

CRR formed the primary goal of the trial, while overall response rate (ORR), duration of response (DOR), progression-free survival (PFS), overall survival (OS) and safety were included as secondary endpoints.

According to primary analysis data, Kymriah induced responses in most subjects who received the treatment, with an ORR of 86%.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The response rates were similar across high-risk subject subgroups in the trial.

However, median DOR in all responders, PFS and OS were not met, Novartis noted. The estimated DOR in subjects with CR and PFS rates were 94% and 76%, respectively at six months.

Furthermore, no grade 3/4 cytokine release syndrome, the most common side effect linked to CAR-T therapy, was observed in the trial subjects.

Novartis Oncology Cell & Gene global head Stefan Hendriks said: “The strength of these pivotal results from the ELARA trial underscore the promising potential of Kymriah in the treatment of patients with relapsed or refractory follicular lymphoma.”

The company plans to seek regulatory approvals globally for Kymriah in r/r FL treatment.

Last month, Novartis decided to terminate the two-year Phase III MERLIN clinical trial of Beovu (brolucizumab) in wet age-related macular degeneration patients despite meeting the primary endpoint.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU